Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab plus VMP vs VMP in newly diagnosed transplant-ineligible multiple myeloma
CTR20171002Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of daratumumab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Sep 2017; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20171002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171002.